Sequence: CRGDKGPDC
| Experiment Id | EXP000726 |
|---|---|
| Paper | Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 e |
| Peptide | iRGD |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 10 mg/kg (in vivo); not specified in vitro |
| Rna Concentration | 100 nM (in vitro); 0.33 mg/kg (in vivo) |
| Mixing Ratio | |
| Formulation Format | co-administration with ROS-sensitive polymeric nanoparticles |
| Formulation Components | iRGD peptide + CA-PLL-TK nanoparticles loaded with siFGL1/siPD-L1 |
| Size Nm | 76.00 |
| Zeta Mv | 6.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | LLC (Lewis lung carcinoma) cells |
| Animal Model | |
| Administration Route | |
| Output Type | protein knockdown |
| Output Value | ~53% FGL1, ~55% PD-L1 reduction |
| Output Units | |
| Output Notes | Enhanced lysosomal escape and cytosolic delivery vs PT-NPs |
| Toxicity Notes | Low cytotoxicity by MTT |
| Curation Notes |